Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Genitourinary Cancers
Which genomic test do you choose for a patient with favorable intermediate prostate cancer trying to decide between active surveillance and treatment?
Answer from: Radiation Oncologist at Academic Institution
Decipher.
Sign In
or
Register
to read more
22021
Related Questions
How would you treat a patient with isolated CNS relapse of seminoma?
How do you design pelvic lymph node treatment volumes for patients with tortuous or aberrant vascular anatomy?
How do you manage bladder spasms during pelvic radiotherapy?
Would you ever re-irradiate the groin/inguinal region?
What are the realistic, modern 10-year survival curves for localized prostate cancer given the improvements we have made in diagnostics and treatment?
Given the different rates of testosterone recovery, do you alter the duration of ADT when using Leuprorelin (GnRH Agonist) vs relugolix (GnRH antagonist) in patients with intermediate or high-risk prostate cancer who received definitive radiation?
How do you manage malignancies in patients with Birt-Hogg-Dubé syndrome (BHD)? Is there concern for increased radiosensitivity?
How do you manage prostate cancer in patients that cannot swallow pills?
What is your preferred approach in a patient unable to fill their bladder during prostate radiotherapy?
Do you utilize daily enemas for patients undergoing prostate SBRT?